Ikena Oncology Income After Taxes 2021-2024 | IKNA

Ikena Oncology income after taxes from 2021 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.

Ikena Oncology Income After Taxes 2021-2024 | IKNA

Ikena Oncology income after taxes from 2021 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$150.5B
Bristol Myers Squibb (BMY)$118.1B
Vertex Pharmaceuticals (VRTX)$115.4B
Gilead Sciences (GILD)$109.4B
CSL (CSLLY)$85.4B
Regeneron Pharmaceuticals (REGN)$81.8B
GSK (GSK)$69.3B
Argenex SE (ARGX)$34.4B
Alnylam Pharmaceuticals (ALNY)$30.2B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$22.6B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$18.3B
Moderna (MRNA)$14.3B
Incyte (INCY)$13.6B
Genmab (GMAB)$13.6B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.8B
Vaxcyte (PCVX)$10.9B
Bio-Techne Corp (TECH)$10.5B
Sarepta Therapeutics (SRPT)$10.2B
Exact Sciences (EXAS)$10B
Exelixis (EXEL)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
QIAGEN (QGEN)$9.3B
Intra-Cellular Therapies (ITCI)$8.8B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$7.5B
Repligen (RGEN)$7.2B